Literature DB >> 36002043

Type 1 diabetes and engineering enhanced islet transplantation.

Abiramy Jeyagaran1, Chuan-En Lu2, Aline Zbinden3, Andreas L Birkenfeld4, Sara Y Brucker5, Shannon L Layland6.   

Abstract

The development of new therapeutic approaches to treat type 1 diabetes mellitus (T1D) relies on the precise understanding and deciphering of insulin-secreting β-cell biology, as well as the mechanisms responsible for their autoimmune destruction. β-cell or islet transplantation is viewed as a potential long-term therapy for the millions of patients with diabetes. To advance the field of insulin-secreting cell transplantation, two main research areas are currently investigated by the scientific community: (1) the identification of the developmental pathways that drive the differentiation of stem cells into insulin-producing cells, providing an inexhaustible source of cells; and (2) transplantation strategies and engineered transplants to provide protection and enhance the functionality of transplanted cells. In this review, we discuss the biology of pancreatic β-cells, pathology of T1D and current state of β-cell differentiation. We give a comprehensive view and discuss the different possibilities to engineer enhanced insulin-secreting cell/islet transplantation from a translational perspective.
Copyright © 2022 The Author(s). Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Biomaterials; Cell and tissue engineering; Cell therapies; Implantation devices; Islet biology

Mesh:

Substances:

Year:  2022        PMID: 36002043      PMCID: PMC9531713          DOI: 10.1016/j.addr.2022.114481

Source DB:  PubMed          Journal:  Adv Drug Deliv Rev        ISSN: 0169-409X            Impact factor:   17.873


  464 in total

1.  A star-PEG-heparin hydrogel platform to aid cell replacement therapies for neurodegenerative diseases.

Authors:  Uwe Freudenberg; Andreas Hermann; Petra B Welzel; Katja Stirl; Sigrid C Schwarz; Milauscha Grimmer; Andrea Zieris; Woranan Panyanuwat; Stefan Zschoche; Dorit Meinhold; Alexander Storch; Carsten Werner
Journal:  Biomaterials       Date:  2009-06-27       Impact factor: 12.479

2.  First GM pigs for allergies. Could xenotransplants be next?

Authors:  Elie Dolgin
Journal:  Nat Biotechnol       Date:  2021-04       Impact factor: 54.908

Review 3.  Stem cell characteristics and the therapeutic potential of amniotic epithelial cells.

Authors:  Toshio Miki
Journal:  Am J Reprod Immunol       Date:  2018-06-29       Impact factor: 3.886

4.  Human and rat beta cells differ in glucose transporter but not in glucokinase gene expression.

Authors:  A De Vos; H Heimberg; E Quartier; P Huypens; L Bouwens; D Pipeleers; F Schuit
Journal:  J Clin Invest       Date:  1995-11       Impact factor: 14.808

5.  Fibroblast growth factor-1 (FGF-1) loaded microbeads enhance local capillary neovascularization.

Authors:  Monica L Moya; Marc R Garfinkel; Xiang Liu; Stephanie Lucas; Emmanuel C Opara; Howard P Greisler; Eric M Brey
Journal:  J Surg Res       Date:  2009-07-10       Impact factor: 2.192

Review 6.  Engineering a Clinically Translatable Bioartificial Pancreas to Treat Type I Diabetes.

Authors:  Gorka Orive; Dwaine Emerich; Ali Khademhosseini; Shinichi Matsumoto; R M Hernández; J L Pedraz; Tejal Desai; Riccardo Calafiore; Paul de Vos
Journal:  Trends Biotechnol       Date:  2018-02-15       Impact factor: 19.536

7.  Pre-culture of mesenchymal stem cells within RGD-modified hyaluronic acid hydrogel improves their resilience to ischaemic conditions.

Authors:  Laura B Gallagher; Eimear B Dolan; Janice O'Sullivan; Ruth Levey; Brenton L Cavanagh; Lenka Kovarova; Martin Pravda; Vladimir Velebny; Tom Farrell; Fergal J O'Brien; Garry P Duffy
Journal:  Acta Biomater       Date:  2020-03-04       Impact factor: 8.947

8.  Generation of insulin-producing pancreatic β cells from multiple human stem cell lines.

Authors:  Nathaniel J Hogrebe; Kristina G Maxwell; Punn Augsornworawat; Jeffrey R Millman
Journal:  Nat Protoc       Date:  2021-08-04       Impact factor: 13.491

Review 9.  Application of hyaluronic acid as carriers in drug delivery.

Authors:  Gangliang Huang; Hualiang Huang
Journal:  Drug Deliv       Date:  2018-11       Impact factor: 6.419

10.  Protection from β-cell apoptosis by inhibition of TGF-β/Smad3 signaling.

Authors:  Ji-Hyeon Lee; Jose Manuel Mellado-Gil; Young Jae Bahn; Sushrut M Pathy; Ying E Zhang; Sushil G Rane
Journal:  Cell Death Dis       Date:  2020-03-13       Impact factor: 8.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.